Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics

Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics

Editor(s): Khalid Iqbal, Sangram S. Sisodia, Bengt Winblad

Published Online: 18 APR 2002

Print ISBN: 9780471521761

Online ISBN: 9780470846452

DOI: 10.1002/0470846453

About this Book

Alzheimer's Disease is an ever present problem affecting millions of people around the world and, as people's average lifespan lengthens, its prevalence is set to increase. A global effort is needed to combat the disease, including research to investigate the causes, development of effective treatments and, ultimately, prevention of the disease. Published every two years, these timely books discuss the very latest research.

This new volume provides a unique source of reference to the important work being done in this field, it gives academics and clinicians an opportunity to learn about cutting edge developments and covers all aspects of Alzheimer's Disease, including diagnosis, clinical course, epidemiological course and therapeutics and disease mechanisms.

Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics will provide essential information for basic and clinical researchers in Alzheimer's Disease and other dementias as well as for those who care for patients.

Table of contents

    1. You have free access to this content
    1. You have free access to this content
  1. Part I: Epidemiology and Risk Factors

  2. Part II: Genetics

    1. Chapter 4

      A Genomic Search for Alzheimer's Disease Genes (pages 31–43)

      Jonathan L. Haines, L. Renee Bailey, Janet M. Grubber, Dale Hedges, Jenifer L. Hall, Sandra West, Leonard Santoro, Beth Kemmerer, Anne M. Saunders, Allen D. Roses, Gary W. Small, William K. Scott, P. Michael Conneally, Jeffery M. Vance and Margaret A. Pericak-Vance

    2. Chapter 5

      Candidate Genes Showing No Evidence of Association with Alzheimer's Disease: Results of the NIMH-AD Genetics Initiative (pages 45–51)

      Lars Bertram, Deborah Blacker, Adam S. Crystal, Jennifer Jones, Devon Keeney, Laura MacKenzie-Ingano, Kristina Mullin, Sanjay Basu, Stephen Yhu, Melvin McInnis, Rodney C. P. Go, Aleister J. Saunders and Rudolph E. Tanzi

    3. Chapter 6

      Familial Alzheimer's Disease with Spastic Paraparesis Associated with a Mutation at Codon 261 of the Presenilin 1 Gene (pages 53–60)

      Martin R. Farlow, Jill R. Murrell, Frederick W. Unverzagt, Michael Phillips, Masaki Takao, Christine Hulette and Bernardino Ghetti

  3. Part III: Diagnosis and Clinical Course

    1. Chapter 10

      Preclinical Prediction of AD: Relation Between Neuropsychological and Neuroimaging Findings (pages 97–110)

      Marilyn S. Albert, Ronald J. Killiany, Keith Johnson, Rudolph E. Tanzi and Kenneth Jones

    2. Chapter 13

      The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials (pages 129–140)

      Michael Grundman, Hyun T. Kim, David Salmon, Martha Storandt, Glenn Smith, Steven Ferris, Richard Mohs, Jason Brandt, Rachelle Doody, Kathleen Welsh-Bohmer, Judith Saxton, Kathy Saine, Frederick Schmitt, Paula Ogrocki, Nancy Johnson, Diane Howieson, Michelle Papka, Joanne Green, Anthony Gamst, Walter Kukull and Leon J. Thal

    3. Chapter 15

      Brain Functional Imaging in Early and Preclinical Alzheimer's Disease (pages 153–164)

      Agneta Nordberg, Vesna Jelic, Eva Arnáiz, Bengt Långström and Ove Almkvist

    4. Chapter 18

      Influence of apoE Genotype and PET Brain Imaging on Preclinical Prediction of Alzheimer's Disease (pages 193–203)

      Gary W. Small, Linda M. Ercoli, Daniel H.S. Silverman, S.-C. Huang, Susan Y. Bookheimer, Helen Lavretsky, Karen Miller, Prabha Siddarth, John C. Mazziotta, Ann M. Saunders, Margaret A. Pericak-Vance, Allen D. Roses, Jorge R. Barrio and Michael E. Phelps

    5. Chapter 26

      CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies (pages 285–291)

      E. Vanmechelen, E. Van Kerschaver, K. Blennow, P. P. De Deyn, D. Galasko, L. Parnetti, C. J. M. Sindic, H. Arai, M. Riemenschneider, H. Hampel, H. Pottel, A. Valgaeren, F. Hulstaert and H. Vanderstichele

    6. Chapter 27

      Increased Levels of a Minor Glycoform of Acetylcholinesterase in Alzheimer's Disease Brain and Cerebrospinal Fluid (pages 293–301)

      Javier Sáez-Valero, Su San Mok, Lisa Fodero, Alberto Marcos, Maria-Sagrario Barquero, Catriona McLean and David H. Small

    7. Chapter 28

      Plasma β-Amyloid as a Surrogate Genetic Marker in Late-Onset Alzheimer's Disease (pages 303–310)

      Nilufer Ertekin Taner, Neill Graff-Radford, Linda H. Younkin, Christopher Eckman, Jennifer Adamson, Daniel J. Schaid, John Blangero, Michael Hutton and Steven G. Younkin

  4. Part IV: Mechanisms of Neurodegeneration

    1. Chapter 32

      Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits (pages 341–361)

      Craig S. Atwood, Xudong Huang, Robert D. Moir, Mark A. Smith, Rudolph E. Tanzi, Alex E. Roher, Ashley I. Bush and George Perry

    2. Chapter 33

      Plasma Antioxidants and Oxidative DNA Damage in Lymphocytes from Normal Aged People and Alzheimer's Disease Patients (pages 363–369)

      Patrizia Mecocci, Maria Cristina Polidori, Tiziana Ingegni, Paola Mattioli, Antonio Cherubini, Marco Catani, Roberta Cecchetti and Umberto Senin

    3. Chapter 34

      Oxidative Damage and Antioxidant Responses in Alzheimer's Disease (pages 371–378)

      George Perry, Akihiko Nunomura, Jesus Avila, Mar Perez, Catherine A. Rottkamp, Craig S. Atwood, Xiongwei Zhu, Gjumrakch Aliev, Adam D. Cash and Mark A. Smith

    4. Chapter 38

      Mechanisms of Aβ Production and Aβ Degradation: Routes to the Treatment of Alzheimer's Disease (pages 421–432)

      D. J. Selkoe, W. Xia, W. T. Kimberly, K. Vekrellis, D. Walsh, W. P. Esler and M. S. Wolfe

    5. Chapter 39

      A High Fat, High Cholesterol Diet Accelerates β-Amyloid Accumulation in the CNS of a Transgenic Mouse Model of Alzheimer's Disease (pages 433–447)

      Lorenzo M. Refolo, Brian Malester, John Lafrancois, Tara Bryant-Thomas, Rong Wang, G. Stephen Tint, Kumar Sambamurti, Karen Duff and Miguel A. Pappolla

    6. Chapter 41

      Accelerated Aβ Generation in a Cell Model of Alzheimer's Disease-related Endosomal–Lysosomal System Upregulation (pages 461–467)

      Paul M. Mathews, Carolyn B. Guerra, Ying Jiang, Benjamin H. Kao, Ravi Dinakar, Pankaj Mehta, Anne M. Cataldo and Ralph A. Nixon

    7. Chapter 44

      Familial British Dementia (pages 487–493)

      Jorge Ghiso, Tamas Révész, Agueda Rostagno, Ruben G. Vidal, Gordon Plant and Blas Frangione

    8. Chapter 46

      A Decamer Duplication in the BRI Gene Originates a de novo Amyloid Peptide that Causes Dementia in a Danish Kindred (pages 507–513)

      Ruben G. Vidal, Tamas Révész, Agueda Rostagno, Toke Bek, Hans Braendgaard, Gordon Plant, Jorge Ghiso and Blas Frangione

    9. Chapter 50

      Functional Consequences of the Association of PS1 with β-Catenin (pages 541–548)

      Salvador Soriano, David E. Kang, Nathalie Chevallier, Hui Zheng and Edward H. Koo

    10. Chapter 53

      Mechanisms of α-Synuclein and NAC Fibrillogenesis (pages 569–586)

      Makoto Hashimoto, Edward Rockenstein, Takato Takenouchi, Margaret Mallory and Eliezer Masliah

    11. Chapter 55

      Phosphorylation, Microtubule Binding and Aggregation of Tau Protein in Alzheimer's Disease (pages 601–607)

      Jesús Ávila, José J. Lucas, Filip Lim, Mar Pérez, Félix Hernández, Montserrat Arrasate, Rosario Armas Portela, Elsa Champion, George Perry, Mark A. Smith and Javier Díaz Nido

  5. Part V: Animal and Cellular Models

    1. Chapter 61

      Lewy-Like Pathology in Mice Transgenic for Mutant (A53T) and Wild-Type Human α-Synuclein (pages 661–670)

      Bernd Sommer, Samuel Barbieri, Katja Hofele, Karl-Heinz Wiederhold, Alphonse Probst, Claudia Mistl, Simone Danner, Sabine Kauffmann, Willibrordus Spooren, Markus Tolnay, Graeme Bilbe and Herman van der Putten

    2. Chapter 63

      Ex Vivo Transmission of Mouse-Adapted Prion Strains to N2a and GT1-7 Cell Lines (pages 679–686)

      Sylvain Lehmann, Hubert Laude, David A. Harris, Richard I. Carp, Didier Vilette, Shigeru Katamine, Jean-Yves Madec and Noriyuki Nishida

    3. Chapter 64

      In Vivo Perturbation of Lysosomal Function Promotes Neurodegeneration in the PS1M146V/APPK670N,M671L Mouse Model of Alzheimer's Disease Pathology (pages 687–695)

      Ralph A. Nixon, Paul M. Mathews, Anne M. Cataldo, Panaiyur S. Mohan, Stephen D. Schmidt, Karen Duff, Martin Berg, Neville Marks, Corinne Peterhoff and Henry Sershen

    4. Chapter 65

      Changes in Cognitive Characteristics of Tg(APP)CRND8 Mice at Early Stages of Immunization with Beta-Amyloid Peptide (pages 697–704)

      Christopher Janus, Jacqueline Pearson, Patrick Horne, Richard Renlund, Karen Parisien, Azhar Chishti, Donna Heslin, Catherine Bergeron, Paul Fraser, Peter St George-Hyslop and David Westaway

  6. Part VI: Therapeutics and Therapeutic Strategies

    1. Chapter 67

      Benefits of Donepezil on Cognition, Function and Neuropsychiatric Symptoms in Patients with Mild and Moderate Alzheimer's Disease over One Year (pages 725–738)

      Gunhild Waldemar, Bengt Winblad, Knut Engedal, Hilkka Soininen, Frans Verhey, Anders Wimo, Anna-Lena Wetterholm, Richard Zhang, Anders Haglund and Ponni Subbiah

    2. Chapter 68

      Characterization of Alzheimer's β-Secretase Protein BACE: Processing and Other Post-translational Modifications (pages 739–745)

      Mitsuru Haniu, Brian D. Bennett, Paul Denis, Yunjen Young, Elizabeth A. Mendiaz, Janis Fuller, John O. Hui, Steven Kahn, Safura Babu-Khan, Sandra Ross, Teresa Burgess, Viswanatham Katta, Margery Nicolson, Jonathan Lull, Shue-Yuan Wang, Gary Rogers, Robert Vassar and Martin Citron

    3. Chapter 72

      Toward the Identification of γ-Secretase: Using Transition State Analog Inhibitors (pages 777–788)

      William P. Esler, W. Taylor Kimberly, Beth L. Ostaszewski, Weiming Xia, Dennis J. Selkoe and Michael S. Wolfe

    4. Chapter 73

      Photoactivated, Active-Site-Directed γ-Secretase Inhibitors Covalently Label Presenilin 1 (pages 789–798)

      Stephen J. Gardell, Yue-Ming Li, Min Xu, Ming-Tain Lai, Qian Huang, Jose L. Castro, Jillian DiMuzio-Mower, Timothy Harrison, Colin Lellis, Alan Nadin, Joseph G. Neduvelil, R. Bruce Register, Mohinder K. Sardana, Mark S. Shearman, Xiao-Ping Shi, Adrian L. Smith, Kuo-Chang Yin and Jules A. Shafer

    5. Chapter 74

      Functional Analysis of β-Secretase Using Mutagenesis and Structural Homology Modeling (pages 799–807)

      Gwen Tatsuno, John Anderson, Jin Hong, David A. Agard, Nobuyuki Ota, Sukanto Sinha, Guriqbal Basi and Lisa McConlogue

    6. Chapter 75

      Therapeutic Approaches to Prion Diseases: In Vitro Studies with Tetracycline Compounds (pages 809–820)

      Tazeen Awan, Gianluigi Forloni, Enzio Ragg, Selina Iussich, Giacomina Rossi, Laura Colombo, Laura Girola, Tania Massignan, Orso Bugiani, Mario Salmona and Fabrizio Tagliavini

  7. Part VII: Psychosocial Care